Research methodology: cancer cachexia syndrome

被引:32
作者
Dahele, M [1 ]
Fearon, KCH [1 ]
机构
[1] Univ Edinburgh, Royal Infirm, Edinburgh EH16 4SA, Midlothian, Scotland
关键词
cancer cachexia; physical activity; trials and end-points;
D O I
10.1191/0269216304pm906ra
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Cachexia is a syndrome and therefore does not have a specific definition. Patients are characterized by the presence of anorexia, early satiety, weight loss, weakness, anaemia and oedema. These features occur to a variable extent in different patients and may change in severity during the course of a patient's illness. The multifactorial origin of cachexia precludes a uniform pathophysiological definition. Taken together these factors have hindered clinical studies both at a fundamental level and in terms of the introduction of effective therapy. The advent of novel therapeutic targets (e.g., ubiquitin-proteasome pathway) and biological response modifiers has opened possibilities for new clinical trials in cachexia. Regulatory authorities feel it is important not only to demonstrate efficacy in terms of patients' nutritional status ( e. g., lean body mass) but also functional status ( e. g., performance status). This article reviews current methods to assess the latter. Methods focused on measuring physical activity level ( e. g., doubly labelled water technique or physical activity meters) promise objective data which can be readily interpreted in terms of clinically meaningful benefit.
引用
收藏
页码:409 / 417
页数:9
相关论文
共 58 条
[1]   Physical activity monitoring based on accelerometry: validation and comparison with video observation [J].
Aminian, K ;
Robert, P ;
Buchser, EE ;
Rutschmann, B ;
Hayoz, D ;
Depairon, M .
MEDICAL & BIOLOGICAL ENGINEERING & COMPUTING, 1999, 37 (03) :304-308
[2]   Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? [J].
Andreyev, HJN ;
Norman, AR ;
Oates, J ;
Cunningham, D .
EUROPEAN JOURNAL OF CANCER, 1998, 34 (04) :503-509
[3]   Unsolved problems in evaluating the quality of life of cancer patients [J].
Ballatori, E .
ANNALS OF ONCOLOGY, 2001, 12 :S11-S13
[4]   Performance status score: do patients and their oncologists agree? [J].
Blagden, SP ;
Charman, SC ;
Sharples, LD ;
Magee, LRA ;
Gilligan, D .
BRITISH JOURNAL OF CANCER, 2003, 89 (06) :1022-1027
[5]   Importance of weight loss definition in the prognostic evaluation of non-small-cell lung cancer [J].
Buccheri, G ;
Ferrigno, D .
LUNG CANCER, 2001, 34 (03) :433-440
[6]  
Cella D, 1998, SEMIN ONCOL, V25, P43
[7]   Advances in quality of life measurements in oncology patients [J].
Cella, D ;
Chang, CH ;
Lai, JS ;
Webster, K .
SEMINARS IN ONCOLOGY, 2002, 29 (03) :60-68
[8]   Placebo effects in oncology [J].
Chvetzoff, G ;
Tannock, IF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (01) :19-29
[9]   What determines the quality of life of terminally ill cancer patients from their own perspective? [J].
Cohen, SR ;
Leis, A .
JOURNAL OF PALLIATIVE CARE, 2002, 18 (01) :48-58
[10]   Quality of life in patients with advanced colorectal cancer: what has been learnt? [J].
Conroy, T ;
Bleiberg, H ;
Glimelius, B .
EUROPEAN JOURNAL OF CANCER, 2003, 39 (03) :287-294